The themes Evolent Health is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
基于 Evolent Health, Inc. 自己向美国证券交易委员会(SEC)提交的申报文件。数字如实呈报,每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议,也不是买卖任何证券的推荐。
US$4.90+2.8%11月13日 收盘
数据截至2026年9月30日,来自2026年11月5日提交的10-Q
公司指引:2026 财年营收 US$2.6B 至 US$2.7B — 同比增长 41.2%
Just reported
From Evolent Health's results release of 2026年11月5日; its quarterly report has since been filed.
Actual
US$725.4M
+51% y/y
+11% q/q
Guided
—
No guide given
Actual
-US$0.21
Guided
—
No guide given
Actual
-US$6.2M
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Grade F-
价格下方的色带显示每个日期的评级,仅依据当时已公开的文件计算。
显示 Evolent Health, Inc. 评级历史 32 个季度中的 2 个。 其余 30 个可回溯到 2019年2月。